[HTML][HTML] Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
KL Reckamp, PH Frankel, N Ruel, PC Mack… - Frontiers in …, 2019 - escholarship.org
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
KL Reckamp, PH Frankel, N Ruel, PC Mack… - Frontiers in …, 2019 - europepmc.org
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
KL Reckamp, PH Frankel, N Ruel… - Frontiers in …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
[HTML][HTML] Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
KL Reckamp, PH Frankel, N Ruel, PC Mack… - Frontiers in …, 2019 - ncbi.nlm.nih.gov
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
[引用][C] Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With …
KL Reckamp, PH Frankel, N Ruel, PC Mack… - Frontiers in …, 2019 - cir.nii.ac.jp
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor
Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal …
Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal …
Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive …
KL Reckamp, PH Frankel, N Ruel, PC Mack… - Frontiers in …, 2019 - pure.psu.edu
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …